Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Trial Profile

A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Itacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 06 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 23 Oct 2018 Planned End Date changed from 1 Jan 2021 to 1 Apr 2021.
    • 23 Oct 2018 Planned primary completion date changed from 1 Nov 2020 to 1 Feb 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top